BreezeBio

Brisbane, Australia · Founded 2016 · $110.0M raised

Headquarters
Brisbane
Employees
51–200
Founded
2016
Business Model
B2B
Total Funding
$110.0M
Last Round
$60.0M Series BFeb 2026
Rounds
3

About

BreezeBio is a biotechnology company developing precision genetic medicines enabled by targeted, non-viral delivery across biologically relevant tissues. Using its proprietary NanoGalaxy platform, the company engineers nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types, with demonstrated delivery to immune cells and tissues in the heart, lung, and central nervous system. BreezeBio is advancing an internal therapeutic pipeline focused on autoimmune disease and oncology, led by BRZ-101, a program designed to restore immune tolerance in Type 1 Diabetes that is advancing into IND-enabling studies.

Summary

BreezeBio is a Biotech company based in Brisbane, Australia, founded in 2016. It has raised $110.0M in total across 3 rounds, most recently a $60.0M Series B round in Feb 2026. Investors include Eli Lilly, Yuanta Investment and DSC Investment.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BFeb 2026
$60.0M

Sign up to see all 3 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

BreezeBio on Indexed.vc
<a href="https://indexed.vc/companies/breezebio"><img src="https://indexed.vc/api/badge/company/breezebio" alt="BreezeBio on Indexed.vc" width="260" height="76" /></a>